HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Helmut Butzkueven Selected Research

Natalizumab (Tysabri)

2/2022Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study.
1/2022Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
1/2022Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
11/2021Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
11/2021Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
8/2021The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.
4/2021Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
1/2021High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients.
1/2021No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
1/2021Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Helmut Butzkueven Research Topics

Disease

73Multiple Sclerosis
04/2022 - 05/2002
31Relapsing-Remitting Multiple Sclerosis
01/2022 - 10/2012
9Demyelinating Diseases (Demyelinating Disease)
03/2016 - 05/2006
8Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/2019 - 04/2008
7Autoimmune Diseases of the Nervous System
07/2022 - 01/2019
5Optic Neuritis (Retrobulbar Neuritis)
03/2022 - 01/2013
4Progressive Multifocal Leukoencephalopathy
02/2022 - 04/2016
4Disease Progression
12/2018 - 01/2011
3Encephalitis (Encephalitis, Rasmussen)
09/2022 - 04/2022
3Tremor (Tremors)
02/2022 - 07/2012
2Glioma (Gliomas)
07/2022 - 05/2022
2Genetic Predisposition to Disease (Genetic Predisposition)
05/2022 - 04/2010
2Atrophy
01/2022 - 07/2019
2COVID-19
11/2021 - 01/2021
2Chronic Progressive Multiple Sclerosis
01/2021 - 01/2019
2Spontaneous Abortion (Miscarriage)
12/2020 - 02/2019
2Inflammation (Inflammations)
05/2020 - 07/2013
2Neuromyelitis Optica (Devic's Disease)
05/2020 - 02/2020
2Seizures (Absence Seizure)
01/2020 - 01/2019
2Autoimmune Diseases (Autoimmune Disease)
06/2014 - 12/2010
1Transverse Myelitis (Necrotizing Myelitis)
03/2022
1Acquired CJD
01/2022
1Drug Resistant Epilepsy
01/2022
1Neoplasms (Cancer)
01/2021
1Infections
01/2021
1Stillbirth
12/2020
1Premature Birth (Birth, Premature)
02/2019
1Cognitive Dysfunction
01/2019
1Anti-N-Methyl-D-Aspartate Receptor Encephalitis
01/2019
1Uveitis
01/2019
1Tuberous Sclerosis (Bourneville's Disease)
01/2019
1Vitamin D Deficiency
12/2018
1Lymphopenia (Lymphocytopenia)
01/2018
1Hypersensitivity (Allergy)
03/2017
1Crush Injuries
01/2016

Drug/Important Bio-Agent (IBA)

23Natalizumab (Tysabri)FDA Link
02/2022 - 04/2014
19Fingolimod Hydrochloride (FTY720)FDA Link
04/2022 - 04/2014
10Biomarkers (Surrogate Marker)IBA
01/2022 - 12/2008
7CladribineFDA LinkGeneric
01/2022 - 10/2018
7InterferonsIBA
01/2022 - 01/2013
7Pharmaceutical PreparationsIBA
10/2021 - 01/2013
6Glatiramer Acetate (Copaxone)FDA Link
01/2022 - 03/2015
5Proteins (Proteins, Gene)FDA Link
05/2022 - 12/2010
5Dimethyl FumarateIBA
01/2022 - 01/2019
4AntibodiesIBA
05/2022 - 01/2016
4Myelin-Oligodendrocyte GlycoproteinIBA
03/2022 - 03/2007
4Vitamin DFDA LinkGeneric
01/2020 - 12/2018
4Leukemia Inhibitory FactorIBA
01/2012 - 05/2006
3AutoantibodiesIBA
09/2022 - 05/2020
3Type A Botulinum Toxins (Botox)FDA Link
02/2022 - 07/2012
3Retinaldehyde (Retinal)IBA
01/2022 - 01/2013
3TabletsIBA
01/2022 - 10/2021
3ocrelizumabIBA
01/2022 - 01/2020
3Alemtuzumab (Campath)FDA Link
11/2021 - 01/2017
3Rituximab (Mabthera)FDA Link
11/2021 - 01/2020
3Interferon-betaIBA
01/2017 - 04/2015
3CuprizoneIBA
06/2015 - 04/2008
2Leucine (L-Leucine)FDA Link
07/2022 - 05/2022
2N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
07/2022 - 04/2022
2teriflunomideIBA
01/2022 - 01/2019
2Monoclonal AntibodiesIBA
05/2021 - 01/2017
2opicinumabIBA
12/2018 - 03/2017
2Interferon beta-1aFDA Link
01/2017 - 01/2013
2HLA-DRB1 Chains (HLA DRB1)IBA
03/2016 - 03/2007
2tyrosine receptor (receptor, tyrosine)IBA
03/2016 - 01/2015
2c-Mer Tyrosine KinaseIBA
03/2016 - 01/2015
2Phosphotransferases (Kinase)IBA
03/2016 - 01/2015
2GalaninIBA
06/2015 - 09/2009
2HLA Antigens (Human Leukocyte Antigens)IBA
10/2010 - 05/2002
1Surface Antigens (Surface Antigen)IBA
09/2022
1Aminobutyrates (Aminobutyric Acid)IBA
07/2022
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
07/2022
11,3-dipropyl-8-phenylxanthineIBA
07/2022
1Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA
05/2022
12'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
04/2022
1Codon (Codons)IBA
01/2022
1siponimodIBA
11/2021
1SolutionsIBA
09/2021
1Complement System Proteins (Complement)IBA
01/2021
1incobotulinumtoxinAFDA Link
05/2020
1Immunoglobulin G (IgG)IBA
02/2020
1Mitoxantrone (Novantrone)FDA LinkGeneric
01/2020
1Membrane Proteins (Integral Membrane Proteins)IBA
01/2020
1GlucocorticoidsIBA
01/2019
1Mechanistic Target of Rapamycin Complex 1IBA
01/2019
1CalciumIBA
01/2018
1Parathyroid Hormone (Parathormone)IBA
01/2018
125-hydroxyvitamin DIBA
01/2018
1Cytidine Diphosphate (CDP)IBA
01/2018
1Transaminases (Aminotransferases)IBA
03/2017
1Biological ProductsIBA
03/2016
1Immunologic Factors (Immunomodulators)IBA
08/2015

Therapy/Procedure

41Therapeutics
02/2022 - 09/2004
8Immunotherapy
04/2022 - 01/2013
5Injections
10/2016 - 07/2012
2Induced Abortion (Induced Abortions)
12/2020 - 02/2019
2Immunomodulation
03/2017 - 04/2016
2Aftercare (After-Treatment)
01/2016 - 07/2012
1Ambulatory Care (Outpatient Care)
08/2020
1Intramuscular Injections
05/2020